Browse > Article

DA-8159, a Potent cGMP Phosphodiesterase Inhibitor, Attenuates Monocrotaline-Induced Pulmonary Hypertension in Rats  

Kang, Kyung-Koo (Research Laboratories, Dong-A Pharm. Co. Ltd.)
Ahn, Gook-Jun (Research Laboratories, Dong-A Pharm. Co. Ltd.)
Sohn, Yong-Sung (Research Laboratories, Dong-A Pharm. Co. Ltd.)
Ahn, Byoung-Ok (Research Laboratories, Dong-A Pharm. Co. Ltd.)
Kim, Won-Bae (Research Laboratories, Dong-A Pharm. Co. Ltd.)
Publication Information
Archives of Pharmacal Research / v.26, no.8, 2003 , pp. 612-619 More about this Journal
Abstract
In this study, we evaluated the effects of oral administration of DA-8159, a selective phosphodiesterase-5 inhibitor, on the development of pulmonary hypertension (PH) induced by monocrotaline (MCT). Rats were administered either MCT (60 mg/kg) or saline. MCT-treated rats were divided into three groups and received orally administered vehicle, or 1 mg/kg or 5 mg/kg of DA-8159, twice a day for twenty-one days. The MCT group demonstrated increased right ventricular weights, medial wall thickening in the pulmonary arteries, myocardial fibrosis and the level of plasma cyclic guanosine monophosphate (cGMP), along with decreased body weight gains. However, DA-8159 markedly and dose-dependently reduced the development of right ventricular hypertrophy and medial wall thickening. DA-8159 also amplified the increase in plasma cGMP level and significantly increased the level of lung cGMP, compared with the MCT group. Although the body weight gain was still lower from the saline-treated control group, DA-8159 demonstrated a significant increase in body weight gains, in both 1 mg/kg and 5 mg/kg groups, when compared with the MCT group. In myocardial morphology, MCT-induced myocardial fibrosis was markedly prevented by DA-8159. These results suggest that DA-8159 may be a useful oral treatment option for PH.
Keywords
Pulmonary hypertension (PH); Monocrotaline (MCT); Phosphodiesterase (PDE) inhibitor; DA-8159;
Citations & Related Records

Times Cited By Web Of Science : 9  (Related Records In Web of Science)
Times Cited By SCOPUS : 8
연도 인용수 순위
1 McMahon, T. J., Ignarro, L. J., and Kadowitz, P. J., Influence of Zaprinast on vascular tone and vasodilator responses in the cat pulmonary vascular bed. J. Appl. Physiol., 74, 1704-1711 (1993)   DOI   PUBMED
2 Pepke-Zaba, J., Higenbottam, T. W., Dinh-Xuan, A. T., Stone, D., and Wallwork, J., Inhaled nitric oxide as a cause of selective pulmonary vasodilatation in pulmonary hypertension. Lancet, 338, 1173-1174 (1991)   DOI   ScienceOn
3 Polson, J. B. and Strada, S. J., Cyclic nucleotide phosphodiesterases and vascular smooth muscle. Annu. Rev. Pharmacol. Toxicol., 36, 403-427 (1996)   DOI   ScienceOn
4 Prasad, S., Wilkinson, J., and Gatzoulis, M. A., Sildenafil in primary pulmonary hypertension. N. Engl. J. Med., 343, 1342 (2000)   DOI   PUBMED   ScienceOn
5 Rich, S., Dantzker, D. R., Ayres, S. M., Bergofsky, E. H., Brundage, B. H., Detre, K. M., Fishman, A. P., Goldring, R. M., Groves, B. M., and Koerner S. K. Primary pulmonary hypertension. A national prospective study. Ann. Intern. Med., 107, 216-223 (1987)   DOI   PUBMED   ScienceOn
6 Schermuly, R. T., Roehl, A., Weissmann, N., Ghofrani, H. A., Leuchte, H., Grimminger, F., Seeger, W., and Walmrath, D., Combination of nonspecific PDE inhibitors with inhaled prostacyclin in experimental pulmonary hypertension. Am. J. Physiol. Lung Cell Mol. Physiol., 281, L1361-L1368 (2001b)   DOI   PUBMED
7 Troncy, E., Francoeur, M., and Blaise, G., Inhaled nitric oxide: clinical applications, indications, and toxicology. Can. J. Anaesth., 44, 973-988 (1997)   DOI   ScienceOn
8 Kodama, K. and Adachi, H., Improvement of mortality by long-term E4010 treatment in monocrotaline-induced pulmonary hypertensive rats. J. Pharmacol. Exp. Ther., 290, 748-752 (1999)   PUBMED
9 Frostell, C., Fratacci, M. D., Wain, J. C., Jones, R., and Zapol, W. M., Inhaled nitric oxide. A selective pulmonary vasodilator reversing hypoxic pulmonary vasoconstriction. Circulation, 83, 2038-2047 (1991)   DOI   PUBMED   ScienceOn
10 Braner, D. A., Fineman, J. R., Chang, R., and Soifer, S. J., M&B 22948, a cGMP phosphodiesterase inhibitor, is a pulmonary vasodilator in lambs. Am. J. Physiol., 264, H252-H258 (1993)   PUBMED
11 Zhao, L., Mason, N. A., Morrell, N. W., Kojonazarov, B., Sadykov, A., Maripov, A., Mirrakhimov, M. M., Aldashev, A., and Wilkins, M. R., Sildenafil inhibits hypoxia-induced pulmonary hypertension. Circulation, 104, 424-428 (2001)   DOI   ScienceOn
12 Shim, H. J., Lee, E. J., Kim, S. H., Yoo, M., Kim, W. B., Lee, H. S., and Lee, M. G., Pharmacokinetics and metabolism of DA-8159, A new PDE5 inhibitor. 8th Asia-Pacific Society for Impotence Research & Exhibition. Thailand, OR5-5 (2001)
13 Barst, R. J., Rubin, L. J., Long, W. A., McGoon, M. D., Rich, S., Badesch, D. B., Groves, B. M., Tapson, V. F., Bourge, R. C., Brundage, B. H., Koerner, S. K., Langleben, D., Keller, C. A., Murali, S., Uretsky, B. F., Clayton, L. M., Jobsis, M. M., Blackburn, S. D., Shortino, D., and Crow, J. W., A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N. Engl. J. Med., 334, 296-302 (1996)⨀ₙ얖⨀⨀ȄĀᣦ⨀ゴ얖⨀裺⨀ĄȀ?⨀낰얖⨀裺⨀ĄȀᣩ⨀얖⨀裺⨀ĄȀ㣩⨀®얖⨀裺⨀ĄȀ䣩⨀?얖⨀裺⨀ĄȀ飨⨀₭얖⨀裺⨀ĄȀ壩⨀䂬얖⨀裺⨀ĄȀ棩⨀傳얖⨀裺⨀ĄȀ⨀悫얖⨀裺⨀ĄȀ磩⨀肪얖⨀裺⨀ĄȀ裩⨀炲얖⨀裺⨀ĄȀ⨀邱얖⨀裺⨀ĄȀࣩ⨀ꂩ얖⨀裺⨀ĄȀ飩⨀삨얖⨀裺⨀ĄȀ꣩⨀얖⨀裺⨀ĄȀ룩⨀§얖⨀裺⨀ĄȀ죩⨀₦얖⨀裺⨀ĄȀ?⨀䂥얖⨀裺⨀ĄȀ⨀?얖⨀裺⨀ĄȀ⨀얖⨀裺⨀ĄȀ࣪⨀ᣃ얖⨀裺⨀ĄȀ   DOI   ScienceOn
14 Weimann, J., Ullrich, R., Hromi, J., Fujino, Y., Clark, M. W., Bloch, K. D., and Zapol, W. M., Sildenafil is a pulmonary vasodilator in awake lambs with acute pulmonary hypertension. Anesthesiology, 92, 1702-1712 (2000)   DOI   ScienceOn
15 Pichardo, J., Palace, V., Farahmand, F., and Singal, P. K., Myocardial oxidative stress changes during compensated right heart failure in rats. Mol. Cell Biochem., 196, 51-57 (1999)   DOI   PUBMED   ScienceOn
16 Rosenkrantz, J. G., Lynch, F. P., and Vogel, J. H., Hypoxic pulmonary hypertension: its modification by dipyridamole. J. Surg. Res., 12, 330-333 (1972)   DOI   ScienceOn
17 Schermuly, R. T., Krupnik, E., Tenor, H., Schudt, C., Weissmann, N., Rose, F., Grimminger, F., Seeger, W., Walmrath, D., and Ghofrani, H. A., Coaerosolization of phosphodiesterase inhibitors markedly enhances the pulmonary vasodilatory response to inhaled iloprost in experimental pulmonary hypertension. Maintenance of lung selectivity. Am. J. Respir. Crit. Care. Med., 164, 1694-1700 (2001a)   DOI   PUBMED   ScienceOn
18 Thomas, M. K., Francis, S. H., and Corbin, J. D., Characterization of a purified bovine lung cGMP-binding cGMP phosphodiesterase. J. Biol. Chem., 265, 14964-14970 (1990)   PUBMED
19 Abrams, D., Schulze-Neick, I., and Magee, A. G., Sildenafil as a selective pulmonary vasodilator in childhood primary pulmonary hypertension. Heart, 84, E4 (2000)   DOI   PUBMED
20 Cohen, A. H., Hanson, K., Morris, K., Fouty, B., McMurty, I. F., Clarke, W., and Rodman, D. M. Inhibition of cyclic 3'-5'-guanosine monophosphate-specific phosphodiesterase selectively vasodilates the pulmonary circulation in chronically hypoxic rats. J. Clin. Invest., 97, 172-179 (1996)   DOI   PUBMED
21 Wilkens, H., Guth, A., Konig, J., Forestier, N., Cremers, B., Hennen, B., Bohm, M., and Sybrecht, G. W., Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension. Circulation, 104, 1218-1222 (2001)   DOI   ScienceOn
22 Ziegler, J. W., Ivy, D. D., Wiggins, J. W., Kinsella, J. P., Clarke, W. R., and Abman, S. H., Effects of dipyridamole and inhaled nitric oxide in pediatric patients with pulmonary hypertension. Am. J. Respir. Crit. Care Med., 158, 1388-1395 (1998)   DOI   PUBMED   ScienceOn
23 Yamaguchi, K., Oka, M., Nishino, M., Hanasato, N., Kira, S., and Fukuchi, Y., E4021, a cGMP phosphodiesterase inhibitor, is a selective pulmonary vasodilator in chronically hypoxic pulmonary hypertensive rats. Nihon Kokyuki Gakkai Zasshi, 36, 23-28 (1998)   PUBMED
24 Dukarm, R. C., Russell, J. A., Morin, F. C $3^{rd}$., Perry, B. J., and Steinhorn, R. H., The cGMP-specific phosphodiesterase inhibitor E4021 dilates the pulmonary circulation. Am. J. Respir. Crit. Care. Med., 160, 858-865 (1999)   DOI   PUBMED   ScienceOn
25 Nakazawa, H., Hori, M., Ozaki, H., and Karaki, H., Mechanisms underlying the impairment of endothelium-dependent relaxation in the pulmonary artery of monocrotaline-induced pulmonary hypertensive rats. Br. J. Pharmacol., 128, 1098-1104 (1999)   DOI   ScienceOn
26 Dinerman, J. L., Lowenstein, C. J., and Snyder, S. H., Molecular mechanisms of nitric oxide regulation. Potential relevance to cardiovascular disease. Circ. Res., 73, 217-222 (1993)   DOI   PUBMED   ScienceOn
27 Takahashi, T., Kanda, T., Inoue, M., Suzuki, T., Kobayashi, I., Kodama, K., and Nagai, R., A selective type V phosphodiesterase inhibitor, E4021, protects the development of right ventricular overload and medial thickening of pulmonary arteries in a rat model of pulmonary hypertension. Life Sci., 59, PL371-PL377 (1996)   DOI   ScienceOn
28 Rosenberg, H. C. and Rabinovitch, M., Endothelial injury and vascular reactivity in monocrotaline pulmonary hypertension. Am. J. Physiol., 255, H1484-H1491 (1998)
29 Schultze, A. E. and Roth, R. A., Chronic pulmonary hypertension- the monocrotaline model and involvement of the hemostatic system. J. Toxicol. Environ. Health B Crit. Rev., 1, 271-346 (1998)   DOI   PUBMED   ScienceOn
30 Chen, L., Gan, X. T., Haist, J. V., Feng, Q., Lu, X., Chakrabarti, S., and Karmazyn, M., Attenuation of compensatory right ventricular hypertrophy and heart failure following monocrotaline-induced pulmonary vascular injury by the $Na^+-H^+$ exchange inhibitor cariporide. J. Pharmacol. Exp. Ther., 298, 469-476 (2001)   PUBMED
31 Dundore, R. L., Clas, D. M., Wheeler, L. T., Habeeb, P. G., Bode, D. C., Buchholz, R. A., Silver, P. J., and Pagani, E. D., Zaprinast increases cyclic GMP levels in plasma and in aortic tissue of rats. Eur. J. Pharmacol., 249, 293-297 (1993)   DOI   ScienceOn
32 Hanasato, N., Oka, M., Muramatsu, M., Nishino, M., Adachi, H., and Fukuchi, Y., E-4010, a selective phosphodiesterase 5 inhibitor, attenuates hypoxic pulmonary hypertension in rats. Am. J. Physiol., 277, L225-L232 (1999)   DOI   PUBMED
33 Cassis, L. A., Rippetoe, P. E., Soltis, E. E., Painter, D. J., Fitz, R., and Gillespie, M. N., Angiotensin II and monocrotaline-induced pulmonary hypertension: effect of losartan (DuP 753), a nonpeptide angiotensin type 1 receptor antagonist. J. Pharmacol. Exp. Ther., 262, 1168-1172 (1992)   PUBMED